# Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

> **NCT00192504** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 31 (actual)

## Conditions studied

- Respiratory Syncytial Virus Prophylaxis

## Interventions

- **BIOLOGICAL:** Motavizumab
- **BIOLOGICAL:** Motavizumab
- **BIOLOGICAL:** Motavizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00192504
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192504, "Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00192504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*